NASDAQ : MGNX
MacroGenics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.38 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 151.61M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 152.88M |
| Enterprise Value | 14.67M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 63.70M |
| Shares Outstanding | 63.70M |
| Shares Change (YoY) | +0.77% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 3.59% |
| Owned by Institutions (%) | 70.43% |
| Float | 56.41M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.87 |
| Forward PS | 1.79 |
| PB Ratio | 3.56 |
| P/TBV Ratio | 3.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.96 |
| Quick Ratio | 2.92 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -225.85% |
| Return on Assets (ROA) | -8.05% |
| Return on Invested Capital (ROIC) | -29.40% |
| Return on Capital Employed (ROCE) | -16.09% |
| Weighted Average Cost of Capital (WACC) | 16.48% |
| Revenue Per Employee | $597,754 |
| Profits Per Employee | -$49,802 |
| Employee Count | 293 |
| Asset Turnover | 0.59 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -777,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.32 |
| 52-Week Price Change | +42.01% |
| 50-Day Moving Average | 3.69 |
| 200-Day Moving Average | 3.42 |
| Relative Strength Index (RSI) | 31.75 |
| Average Volume (20 Days) | 975,501 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.06M |
| Short Previous Month | 7.04M |
| Short % of Shares Out | 7.94% |
| Short % of Float | 8.97% |
| Short Ratio (days to cover) | 8.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 175.14M |
| Gross Profit | -1.30M |
| Operating Income | -38.06M |
| Pretax Income | -101.83M |
| Net Income | -14.59M |
| EBITDA | -32.17M |
| EBIT | -38.06M |
| Loss Per Share | -$0.23 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 173.31M |
| Total Debt | 35.09M |
| Net Cash | 138.21M |
| Net Cash Per Share | $2.17 |
| Equity (Book Value) | 42.87M |
| Book Value Per Share | 0.67 |
| Working Capital | 212.87M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -63.72M |
| Capital Expenditures | -1.82M |
| Depreciation & Amortization | 5.89M |
| Net Borrowing | n/a |
| Free Cash Flow | -65.54M |
| FCF Per Share | -$1.03 |
Margins
| Measure | Value |
|---|
| Gross Margin | -0.74% |
| Operating Margin | -21.73% |
| Pretax Margin | -58.14% |
| Profit Margin | -8.33% |
| EBITDA Margin | -18.37% |
| EBIT Margin | -21.73% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.77% |
| Shareholder Yield | n/a |
| Earnings Yield | -9.75% |
| FCF Yield | -42.87% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.00 |
| Price Target Difference | 233.33% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -15.52% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.95 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |